Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Tumor volume regression of rectal cancer in daily MRI during preoperative chemoradiotherapy with capecitabine.
Authors
Yoo-Kang Kwak
Catholic Medical Center, Incheon, South Korea
Yoo-Kang Kwak , Sea-Won Lee , Yoon Ju Jung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.123
Abstract #
123
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
A new radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemoradiation in locally advanced or unresectable rectal cancer: The dose-finding part of a phase I/II trial.
First Author: Jaw-Yuan Wang
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2022 ASCO Annual Meeting
Phase 1b/2 study of a radio-enhancer, PEP503 (NBTXR3), in combination with concurrent chemo-radiation in locally advanced or unresectable rectal cancer.
First Author: Ching-Wen Huang